Extrawell Pharmaceutical Holdings (0858) Fair Value & Analysis
Healthcare · HK · Market cap HK$186M
Fair value as of: Aug 13, 2026
From 8 valuation models · updated 2 days ago
Below-average quality, and screening another 25% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.0678). The favourable scenario is already priced in.
- Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$0.0260 – HK$0.1760 · fair‑value band HK$0.0436 – HK$0.0678 · the HK$0.0790 price screens above the HK$0.0595 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Extrawell Pharmaceutical Holdings (0858) currently trades at HK$0.0790, while our model-based Fair Value estimate is HK$0.0595, implying the stock looks roughly 24.7% overvalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Trailing-twelve-month revenue stands at HK$52.6M. Revenue declined 9.0% year over year. It earns a return on equity of -32.0%. Net debt stands at HK$63.2M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.0436 (bear case) to HK$0.0678 (bull case); at HK$0.0790, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 47% below its 52-week high and 46% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -25%, 0858 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 8 models by family
Widest divergence: Multiples (HK$1.31) versus Asset-Based (HK$0.3100). Highest evidence: Residual Income (76).
Notify me when 0858 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 32
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sell of pharmaceutical products in the People's Republic of China and Hong Kong.
Full company description
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sell of pharmaceutical products in the People's Republic of China and Hong Kong. The company manufactures transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing; and ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. It is also involved in marketing and distribution of imported pharmaceutical products, including Skin-Cap for the treatment of itching, irritation, redness, and scaly skin issues; and Millibar for the treatment of high blood pressure. In addition, the company develops oral insulin product, which is in clinical trial stage for the treatment of diabetes. Further, the company engages in the provision of agency services and property investment business. Extrawell Pharmaceutical Holdings Limited was incorporated in 1998 and is headquartered in Quarry Bay, Hong Kong.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Extrawell Pharmaceutical Holdings reported revenue of HK$55.4M in FY2025 versus HK$78.8M in FY2021, a compound −8.4%/yr. Reported net income was HK$223M in FY2025.
0858 screens 25% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Extrawell Pharmaceutical Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Extrawell Pharmaceutical Holdings (0858) overvalued or undervalued?
What is the fair value of 0858?
What is the quality score of 0858?
What is the revenue of Extrawell Pharmaceutical Holdings (0858)?
What is the net profit margin of 0858?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Extrawell Pharmaceutical Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.